3 research outputs found

    МодСль прогнозирования ΠΈ управлСния ΠΏΡ€Π΅ΠΆΠ΄Π΅Π²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹ΠΌΠΈ Ρ€ΠΎΠ΄Π°ΠΌΠΈ

    Get PDF
    Background: It seems relevant to study the contribution of socio-demographic, somatic and obstetric-gynecological factors in the implementation of preterm birth. Aims: Assessment of the prognostic significance of socio-demographic, obstetric-gynecological and somatic factors in the prediction of preterm birth and associated adverse pregnancy outcomes with subsequent validation of the prognostic model. Materials and methods: Cohort study with a mixed cohort. A retrospective assessment of socio-demographic factors, harmful habits, obstetric and gynecological pathology, somatic diseases, course and outcomes of pregnancy was carried out with the assessment of the status of newborns in 1246 women with subsequent construction of a predictive model of preterm birth and adverse outcomes of pregnancy using Regression with Optimal Scaling and its prospective validation in 100 women. Results: The most significant predictors, that increase the chance of preterm birth and adverse pregnancy outcomes, were history of premature birth, irregular monitoring during pregnancy, history of pelvic inflammatory disease, smoking, obesity, the onset of sexual activity up to 16 years, cardiovascular and endocrine diseases. Intellectual job reduced the chance of preterm birth and adverse pregnancy outcomes This multivariate predictive model has a diagnostic value. The score of risk factors 25 points had a sensitivity of 73%, a specificity of 71%, the area under the ROC curve (AUC) 0.76 (good quality), p0.001. After stratification of high-risk groups by maternal and perinatal pathology the following list of diagnostic and therapeutic measures is introduced and actively implemented in antenatal clinics. To stratificate this model, we prospectively analyze the course and pregnancy outcomes of 100 women divided into 2 groups: group 1 ― 50 women with preterm delivery, group 2 ― 50 women with term delivery. A total score of 25 and above had 44% of women in group 1 and only 10% of women in group 2 (sensitivity 81.4%, specificity 61.6%, positive predictive value 44%, negative predictive value 90%, positive likelihood ratio 2.2 [1.53.0], negative likelihood ratio 0.3 [0.130.68]). Conclusions: We have proposed a model for predicting preterm birth and delivery and perinatal losses using the available characteristics of pregnant women from early pregnancy with moderate indicators of diagnostic value. Further validation of the model in the general population of pregnant women is required.ОбоснованиС. ΠŸΡ€Π΅Π΄ΡΡ‚Π°Π²Π»ΡΠ΅Ρ‚ΡΡ Π°ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½Ρ‹ΠΌ ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅ Π²ΠΊΠ»Π°Π΄Π° ΡΠΎΡ†ΠΈΠ°Π»ΡŒΠ½ΠΎ-дСмографичСских, соматичСских ΠΈ Π°ΠΊΡƒΡˆΠ΅Ρ€ΡΠΊΠΎ-гинСкологичСских Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² Π² Ρ€Π΅Π°Π»ΠΈΠ·Π°Ρ†ΠΈΡŽ ΠΏΡ€Π΅ΠΆΠ΄Π΅Π²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Ρ… Ρ€ΠΎΠ΄ΠΎΠ². ЦСль исслСдования ― ΠΎΡ†Π΅Π½ΠΊΠ° значимости ΡΠΎΡ†ΠΈΠ°Π»ΡŒΠ½ΠΎ-дСмографичСских, Π°ΠΊΡƒΡˆΠ΅Ρ€ΡΠΊΠΎ-гинСкологичСских ΠΈ соматичСских Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² Π² ΠΏΡ€ΠΎΠ³Π½ΠΎΠ·ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡ€Π΅ΠΆΠ΄Π΅Π²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Ρ… Ρ€ΠΎΠ΄ΠΎΠ² ΠΈ ассоциированных с Π½ΠΈΠΌΠΈ нСблагоприятных исходов бСрСмСнности с ΠΏΠΎΡΠ»Π΅Π΄ΡƒΡŽΡ‰Π΅ΠΉ Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°Ρ†ΠΈΠ΅ΠΉ прогностичСской ΠΌΠΎΠ΄Π΅Π»ΠΈ. ΠœΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠšΠΎΠ³ΠΎΡ€Ρ‚Π½ΠΎΠ΅ исслСдованиС со ΡΠΌΠ΅ΡˆΠ°Π½Π½Ρ‹ΠΌΠΈ Π³Ρ€ΡƒΠΏΠΏΠ°ΠΌΠΈ участников. ΠŸΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡŒ рСтроспСктивная ΠΎΡ†Π΅Π½ΠΊΠ° ΡΠΎΡ†ΠΈΠ°Π»ΡŒΠ½ΠΎ-дСмографичСских Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ², Π²Ρ€Π΅Π΄Π½Ρ‹Ρ… ΠΏΡ€ΠΈΠ²Ρ‹Ρ‡Π΅ΠΊ, соматичСских Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, гинСкологичСской ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΠΈ, тСчСния ΠΈ исходов бСрСмСнности для Π½ΠΎΠ²ΠΎΡ€ΠΎΠΆΠ΄Π΅Π½Π½Ρ‹Ρ… Ρƒ 1246 ΠΆΠ΅Π½Ρ‰ΠΈΠ½ с Ρ†Π΅Π»ΡŒΡŽ построСния ΠΌΠΎΠ΄Π΅Π»ΠΈ прогнозирования ΠΏΡ€Π΅ΠΆΠ΄Π΅Π²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Ρ… Ρ€ΠΎΠ΄ΠΎΠ² ΠΈ нСблагоприятных исходов бСрСмСнности ΠΏΡ€ΠΈ ΠΏΠΎΠΌΠΎΡ‰ΠΈ рСгрСссионного Π°Π½Π°Π»ΠΈΠ·Π° с ΠΎΠΏΡ‚ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹ΠΌ ΡˆΠΊΠ°Π»ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈ Π²Π°Π»ΠΈΠ΄ΠΈΠ·Π°Ρ†ΠΈΠ΅ΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ Ρƒ 100 ΠΆΠ΅Π½Ρ‰ΠΈΠ½. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. НаиболСС Π·Π½Π°Ρ‡ΠΈΠΌΡ‹ΠΌΠΈ ΠΏΡ€Π΅Π΄ΠΈΠΊΡ‚ΠΎΡ€Π°ΠΌΠΈ, ΡƒΠ²Π΅Π»ΠΈΡ‡ΠΈΠ²Π°ΡŽΡ‰ΠΈΠΌΠΈ риск ΠΏΡ€Π΅ΠΆΠ΄Π΅Π²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Ρ… Ρ€ΠΎΠ΄ΠΎΠ² ΠΈ нСблагоприятных исходов бСрСмСнности, оказались ΠΏΡ€Π΅ΠΆΠ΄Π΅Π²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Π΅ Ρ€ΠΎΠ΄Ρ‹ Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅, нСрСгулярноС наблюдСниС Π²ΠΎ врСмя бСрСмСнности, Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Π΅ заболСвания ΠΎΡ€Π³Π°Π½ΠΎΠ² ΠΌΠ°Π»ΠΎΠ³ΠΎ Ρ‚Π°Π·Π° Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅, ΠΊΡƒΡ€Π΅Π½ΠΈΠ΅, ΠΎΠΆΠΈΡ€Π΅Π½ΠΈΠ΅, Π½Π°Ρ‡Π°Π»ΠΎ ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΉ ΠΆΠΈΠ·Π½ΠΈ Π΄ΠΎ 16 Π»Π΅Ρ‚, сСрдСчно-сосудистыС ΠΈ эндокринныС заболСвания. ΠŸΡ€ΠΈΠ½Π°Π΄Π»Π΅ΠΆΠ½ΠΎΡΡ‚ΡŒ ΠΊ ΠΈΠ½Ρ‚Π΅Π»Π»Π΅ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½ΠΎΠΉ Ρ€Π°Π±ΠΎΡ‚Π΅, Π½Π°ΠΎΠ±ΠΎΡ€ΠΎΡ‚, ΡƒΠΌΠ΅Π½ΡŒΡˆΠ°Π»Π° риск ΠΏΡ€Π΅ΠΆΠ΄Π΅Π²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Ρ… Ρ€ΠΎΠ΄ΠΎΠ² ΠΈ ассоциированных с Π½ΠΈΠΌΠΈ нСблагоприятных исходов. Данная прогностичСская модСль продСмонстрировала Π΄ΠΈΠ°Π³Π½ΠΎΡΡ‚ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ Ρ†Π΅Π½Π½ΠΎΡΡ‚ΡŒ. ΠŸΡ€ΠΈ подсчСтС 25 ΠΈ Π±ΠΎΠ»Π΅Π΅ Π±Π°Π»Π»ΠΎΠ² модСль ΠΈΠΌΠ΅Π»Π° Ρ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ 73%, ΡΠΏΠ΅Ρ†ΠΈΡ„ΠΈΡ‡Π½ΠΎΡΡ‚ΡŒ 71%, ΠΏΠ»ΠΎΡ‰Π°Π΄ΡŒ ΠΏΠΎΠ΄ ROC-ΠΊΡ€ΠΈΠ²ΠΎΠΉ (AUC) 0,76 (качСство Ρ…ΠΎΡ€ΠΎΡˆΠ΅Π΅), Ρ€0,001. ПослС стратификации Π³Ρ€ΡƒΠΏΠΏ высокого риска ΠΏΠΎ матСринской ΠΈ ΠΏΠ΅Ρ€ΠΈΠ½Π°Ρ‚Π°Π»ΡŒΠ½ΠΎΠΉ ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π² условиях ТСнской ΠΊΠΎΠ½ΡΡƒΠ»ΡŒΡ‚Π°Ρ†ΠΈΠΈ Π²Π½Π΅Π΄Ρ€Π΅Π½ ΠΈ Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎ проводится ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Π½Ρ‹ΠΉ ΠΏΠ΅Ρ€Π΅Ρ‡Π΅Π½ΡŒ диагностичСских ΠΈ Π»Π΅Ρ‡Π΅Π±Π½ΠΎ-профилактичСских мСроприятий. Π‘ Ρ†Π΅Π»ΡŒΡŽ стратификации ΠΌΠΎΠ΄Π΅Π»ΠΈ проспСктивно ΠΏΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Ρ‹ Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ ΠΈ исходы бСрСмСнности Ρƒ 100 ΠΆΠ΅Π½Ρ‰ΠΈΠ½, Ρ€Π°Π·Π΄Π΅Π»Π΅Π½Π½Ρ‹Ρ… Π½Π° 2 Π³Ρ€ΡƒΠΏΠΏΡ‹ ΠΏΠΎ 50 Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊ, Ρ‡ΡŒΡ Π±Π΅Ρ€Π΅ΠΌΠ΅Π½Π½ΠΎΡΡ‚ΡŒ Π·Π°ΠΊΠΎΠ½Ρ‡ΠΈΠ»Π°ΡΡŒ ΠΏΡ€Π΅ΠΆΠ΄Π΅Π²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹ΠΌΠΈ ΠΈΠ»ΠΈ своСврСмСнными Ρ€ΠΎΠ΄Π°ΠΌΠΈ. Π’ Π³Ρ€ΡƒΠΏΠΏΠ΅ 1 суммарный Π±Π°Π»Π» 25 ΠΈΠΌΠ΅Π»ΠΈ 44% ΠΆΠ΅Π½Ρ‰ΠΈΠ½, Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ 2 ― Ρ‚ΠΎΠ»ΡŒΠΊΠΎ 10% ΠΆΠ΅Π½Ρ‰ΠΈΠ½ (Ρ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ 81,4%, ΡΠΏΠ΅Ρ†ΠΈΡ„ΠΈΡ‡Π½ΠΎΡΡ‚ΡŒ 61,6%, ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Π°Ρ прогностичСская Π·Π½Π°Ρ‡ΠΈΠΌΠΎΡΡ‚ΡŒ 44%, ΠΎΡ‚Ρ€ΠΈΡ†Π°Ρ‚Π΅Π»ΡŒΠ½Π°Ρ прогностичСская Π·Π½Π°Ρ‡ΠΈΠΌΠΎΡΡ‚ΡŒ 90%, ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ΅ ΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠ΅ правдоподобия 2,2 [1,53,0], ΠΎΡ‚Ρ€ΠΈΡ†Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠ΅ ΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠ΅ правдоподобия 0,3 [0,130,68]). Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Нами ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π° модСль прогнозирования ΠΏΡ€Π΅ΠΆΠ΄Π΅Π²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Ρ… Ρ€ΠΎΠ΄ΠΎΠ² ΠΈ ΠΏΠ΅Ρ€ΠΈΠ½Π°Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… ΠΏΠΎΡ‚Π΅Ρ€ΡŒ с использованиСм доступных характСристик Π±Π΅Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Ρ… ΠΆΠ΅Π½Ρ‰ΠΈΠ½ с Ρ€Π°Π½Π½ΠΈΡ… сроков бСрСмСнности с ΡƒΠΌΠ΅Ρ€Π΅Π½Π½Ρ‹ΠΌΠΈ показатСлями диагностичСской значимости. ВрСбуСтся дальнСйшая валидизация ΠΌΠΎΠ΄Π΅Π»ΠΈ Π½Π° большСй популяции Π±Π΅Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Ρ… ΠΆΠ΅Π½Ρ‰ΠΈΠ½

    Empirical therapy for vulvovaginitis in reproductive-aged women in routine clinical practice

    No full text
    Objective. To evaluate the efficiency of empirical therapy with tergynan in reproductive-aged women in routine clinical practice. Subjects and methods. The TERRA multicenter post-registration observational study enrolled 430 reproductive-aged patients diagnosed with acute vulvovaginitis. Based on their complaints, clinical symptoms, and objective examination, the patients received empirical therapy with the combination antimicrobial drug Tergynan as a single vaginal tablet once daily for 10 days. Gynecological examination, pH-metry, and bacterioscopic and bacteriological examinations of discharge (Femoflor-16) were performed, and the time course of changes in clinical symptoms evaluated. Results. There was less vaginal discharge, a complete disappearance of unpleasant odor, and a feeling of vaginal itching and burning (74.5 and 67.1%, respectively). There were increases in the detection rate of Lactobacillus spp. by 2 times with a dissemination level of 106-107 CFU/ml, in the suppression of obligate anaerobic representatives (associations of Gardnerella vaginalis + Prevotella bivia + Porphyromonas spp., as well as Eubacterium spp.) by 5 times, facultative anaerobic bacteria (Enterobacteriaceae and Streptococcus spp.) by 3 times, and yeast-like fungi of the genus Candida by 2 times. Conclusion. This investigation demonstrated the high clinical (96.5%) and microbiological (97.3%) efficiency of empirical therapy with tergynan in 430 reproductive-aged women with acute nonspecific vulvovaginitis. Β© 2020, Bionika Media Ltd. All rights reserved
    corecore